迈博药业-B2023年度报告

2023 24581237111132140163168169171172174256257262 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands G79225300 183171712-1716 8318A 97927 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 1 50037 2181 123 www.mabpharm.cn CMAB008®CMAB008®PIC/SGMP CMAB007®IgECMAB007®34GPO CMAB009NDAmCRCEGFRCMAB009CMAB009 CMAB807CMAB015PIC/SGMP GMP40,000CDMO PIC/S 913 ✓CMAB008®S202100251234656CMAB008®GMPCMAB008® CMAB008®1,000CMAB008®MIS-C3,142CMAB008®CMAB008®CMAB008®CMAB008®GMPPIC/SGMP ✓CMAB007®S2023003075mgS20230031150mgIgECMAB007®H112CMAB007®IIIIgECMAB007®CMAB007® CMAB007®CMAB007®CMAB007®34GPOCMAB007® ✓CMAB009CMAB009EGFRFOLFIRImCRCCMAB009CMAB009EGFRCMAB009mCRCEGFR CMAB009CMAB009CMAB009mCRCEGFRCMAB009CMAB009 CMAB009CMAB009CMAB009 CMAB015CMAB015IIIICMAB807IIINDACMAB807X2022LP00032CMAB017EGFRCMAB017CMAB022 203863 5,000GMPGMP40,000CDMO PIC/SGMP ®–CMAB008 CMAB008®TNFS20210025 (i)(ii)(iii)(iv)6(v)(vi) CMAB008®CMAB008®CHOTNFTNFCMAB008®TNFTNFCMAB008®CMAB008® CMAB008®CMAB008®1,000IBD CMAB008®CMAB008®GPOCMAB008®GMPPIC/SGMP ®CMAB007 CMAB007®IgEIgECMAB007®IgEIgEIgECMAB007®4824CMAB007®CMAB007®CMAB007® CMAB007®S2023003075mgS20230031150mgIgENDACMAB007®H112CXSL230037775mgCXSL2300378150mgCMAB007®NDACMAB007®CMAB007®CMAB007®CMAB007®CMAB007®34GPOCMAB007® CMAB009 CMAB009EGFRFOLFIRImCRCCMAB009CMAB009EGFRCMAB009mCRCEGFR CMAB009NDACMAB009CMAB009mCRCEGFRCMAB009 CMAB009 CMAB807RANKLBG2IgG2RANKLCMAB807RANKLRANKRANKLRANKCMAB807IIICMAB807 CMAB807CMAB807XCMAB807X CMAB819ICMAB819ICMAB819CMAB819 CMAB017EGFRCMAB017G1IgG1FcCMAB017CMAB017CMAB017CMAB017CMAB01724-72CMAB017 CMAB015secukinumabCMAB01517AIL-17ACMAB015IIIICMAB015 CMAB022®stelara®ustekinumab12IL-1223IL-23IL-12IL-23p40IL-12R1IL-12IL-23FDAUNITI-1UNITI-2IM-UNITITNFCMAB022IIII CMAB023TSLPIgG2-lambdaTEZSPIRETezepelumabTSLPTSLPTSLPCMAB023 CMAB016®Dupixent®dupilumabG4IgG4CMAB0164IL-4IL-413IL-13FDABOREASNOTUS52(COPD)30%34%52FDA6sBLACOPDCMAB016 CMAB008CMAB007CMAB009NDACMAB807NDAGMP 30,000(i)3×1,500(ii)400(iii)100CMAB008CMAB007GMP 100,746(i)7,50018,000(ii)GMP40,000 CMAB008®GMPPIC/SGMP (i)(ii) GMPGMP PIC/S CMAB008CMAB007CMAB009CMAB807CMAB015 55.955.9%87.2 15.422.5%11.9 27.386.9%3.6 4.770.8%1.4 147.916.7%123.2 90.615.6%104.7 7.233.2%9.6 33.6416.4%173.3CMAB007CMAB009 50.3209.722.5 50.3 288100,74634.350,835102.549.0200.2100.0 412,4084,124,080,000 80.2%19.8%56.3%43.7% 100%80.2%56.3% (1) (2) 1.10.50.8 ESGESGESG C2ESG 02181.HK www.hkexnews.hkwww.mabpharm.cn 1.ESG ESGESGESG 1.1ESG ESGESGESGESGESGESGESGESGESG 1.2 ESG 1.3 ESGESGESG22 2. 2.1 2.1.1 2.1.2 91 2.2 2.2.1 2.2.2 2.2.3 3 3.1 3.1.1 GMP2 LIMS3EMS4BMS5 25017372%123,211 CMAB008CMAB007CMAB009 3.1.2 124282111 3.2 3.2.1 EMA7 PIC/S8 EP9 USP10WHO11 PDA12 ISPE13CAPA14 CAPA GMPCAPACCS15CCS GMPEMAPIC/SEMAPIC/S GMP 臨床研究質量管理 產品/物料質量管理 GMPGMPGMP 2865 CAPA 建立投訴或反饋的信息收集與記錄機制，對投訴或反饋內容進行初步判斷並轉交至相應部門核實和處理 調查和核實投訴或反饋的內容，了解問題發生的原因和影響範圍 根據調查結果，采取相應的CAPA措施，避免類似問題再次發生 72® 3.2.2 4 4.1 4.1.1 GMP 75624 24 4.1.2 4.2 5 5.1 (ISSB)2 5.2 EHS26 5.3 5.3.1 SOP-ED-EQ-012G79(COD)COD4GB8978GB18918 5.3.2 20 24 5.3.3 EHS 5.4 5.4.1 ••• •50min20min60%•31 ••• •• 2 5.4.2 5.4.3 6 6.1 6.1.1 347100%72 122 29.32% 6.1.2 6.2 6.2.1 SOP1,8112,8973756001,4242,201129638,264110 6.2.2 25 6.3 EHS600 6.4 6.4.1 6.4.2 PK + 7 1,000®257,000 I-III / 1 388(2)5 36 4047 168170 RO 13.91C237110 1. •• 2. • 3. • 4. • 5. • 6. •• (1)(2)(3)147151 108112 3.133.13 33 33D2 31.6%16.2% 46.0%21.3% 5% 10 8.10 Sinomab 256 15 28 257,0001,000296,0002,000 1711,333.81,334.8 25 XV(i)XV78(ii)352(iii)10 (1)4,124,080,000 (2)29 XV78352 336 (1)Asia Mabtech49.95%4.05%Asia Mabtech100%Asia MabtechAsia Pacific Immunotech VentureAsia Pacific Immunotech VentureXV167,025,000Asia Mabtech2,059,975,000 (2)CDH PE18.00%CDH PECDH FundCDH FundCDH PECDH FundCDH VCDH VChina Diamond V80%ChinaDiamond VChina Diamond100%(3)FH InvestmentLink Best Capital LimitedLink Best Capital Limited 336 2.5% 1020% 1.50 6283,512,50083,512,500212176,121,5021.85% 29 3314A 14A Sinomab5%61.67%Sinomab CMAB807 CMAB807IIICMAB807 CMAB807CMAB807III(i)CMAB807III(ii)(iii)CMAB807CMAB807(iv)CMAB807 (i)CMAB807CMAB807(ii) CMAB807 CMAB8073 CMAB8072,866,000162,000 CMAB807 CDMO CDMOCDMOCMAB807 CDMOCMAB807(a)(b)(c) CDMO48CDMOCMAB807205 CDMO CDMO18 CDMOCMAB807CDMO (i)(ii)(iii) (1)(2)(3) 14A3314A14A14A 1,144.5 347102245 (1)27 250173 55 24 47 20 51 4620 58 CDH Investments Management Company Limited2319105500089583080602880329300630 4825 59 68 41108GEM83601259GEM8229 10 55 47 51 46 3818258340142938938158960810026081957 & Co.HospitalityLimited8495 GEM8202(i)(ii)(iii)(iv)(v)195,000HCCW82/2020 109614001439756ROMA 13.51B(1) C1 C3 3.09D 3.10(1)3.10(2)3.10A(1)(2) (i)(ii)(iii)(iv) C.1.4 1 1. (i)(ii) (i)CMAB007®(ii)CMAB009(iii)(iv)CMAB807III150(v)CMAB809C.5.1C.2.7 1.2